Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) Director Wendy B. Young bought 6,000 shares of the company’s stock in a transaction on Wednesday, March 12th. The shares were acquired at an average cost of $10.21 per share, for a total transaction of $61,260.00. Following the completion of the acquisition, the director now directly owns 6,000 shares of the company’s stock, valued at $61,260. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Rapport Therapeutics Stock Up 4.9 %
RAPP stock opened at $10.51 on Friday. Rapport Therapeutics has a fifty-two week low of $6.43 and a fifty-two week high of $29.74. The firm’s 50-day simple moving average is $13.54 and its 200 day simple moving average is $18.73. The stock has a market cap of $383.57 million and a PE ratio of -0.76.
Institutional Trading of Rapport Therapeutics
A number of large investors have recently modified their holdings of RAPP. TRV GP V LLC acquired a new stake in shares of Rapport Therapeutics in the 4th quarter worth about $126,579,000. TRV GP VI LLC acquired a new stake in shares of Rapport Therapeutics in the 4th quarter worth about $17,194,000. FMR LLC increased its holdings in shares of Rapport Therapeutics by 10.1% in the 3rd quarter. FMR LLC now owns 5,486,468 shares of the company’s stock worth $112,363,000 after acquiring an additional 503,117 shares during the period. Geode Capital Management LLC acquired a new stake in shares of Rapport Therapeutics in the 3rd quarter worth about $4,133,000. Finally, Price T Rowe Associates Inc. MD grew its position in Rapport Therapeutics by 9.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,143,384 shares of the company’s stock valued at $20,285,000 after buying an additional 95,976 shares in the last quarter.
About Rapport Therapeutics
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Featured Stories
- Five stocks we like better than Rapport Therapeutics
- Compound Interest and Why It Matters When Investing
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Insider Trades May Not Tell You What You Think
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What Are Some of the Best Large-Cap Stocks to Buy?
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
